News

Public · Published

Bambusa Therapeutics to Sell 9.4 Million Shares at $15-$17 Each in IPO

Bambusa Therapeutics plans to sell nearly 9.4 million shares at $15 to $17 each in its initial public offering, expecting about $134.9 million in net proceeds at the $16 midpoint. The company applied to list on Nasdaq under BBTX.

Published:

Updated:

What happened

Bambusa Therapeutics plans to sell nearly 9.4 million shares at $15 to $17 each in its initial public offering, expecting about $134.9 million in net proceeds at the $16 midpoint. The company applied to list on Nasdaq under BBTX.

Confirmed

Global impact / market context

The IPO would give Bambusa cash to fund its operating expenses and capital spending into late 2028, which means money for day-to-day operations and long-term investments. That funding runway reduces the need to raise money again soon while it develops its antibody treatments.

Analyst inference

At the $16 midpoint, Bambusa would have nearly 51.2 million shares outstanding if underwriters buy extra shares, implying a market capitalization of about $820 million. That valuation puts it among other clinical-stage biotech listings seeking public money for drug development.

Analyst inference

What to watch

  1. Watch whether the IPO prices within the stated $15 to $17 per-share range, as Bambusa plans to sell nearly 9.4 million shares and expects net proceeds of about $134.9 million at the $16 midpoint. Confirmed
  2. Watch whether underwriters exercise their option to buy an additional 1.41 million shares, which would raise expected net proceeds to around $155.8 million and increase shares outstanding. Proposed
  3. Watch how much cash Bambusa actually spends on operating expenses and capital spending, since the company expects its proceeds plus existing resources to last only into late 2028. Analyst inference

Evidence

  • Original source link unavailable